Comparison of the Adverse Events Associated with MF59-Adjuvanted and Non-Adjuvanted H1N1 Vaccines in Healthy Young Male Korean Soldiers
-
- Hwang Se-Min
- Department of Preventive Medicine, Armed Forces Medical Command
-
- Kim Hack-Lyoung
- Department of Internal Medicine, Seoul National University Hospital
-
- Min Kyueng-Whan
- Armed Forces Seoul Hospital
-
- Kim Min
- Armed Forces Seoul Hospital
-
- Lim Jae-Sung
- Armed Forces Seoul Hospital
-
- Choi Jin-Man
- Armed Forces Seoul Hospital
-
- Chun Byung-Chul
- Department of Preventive Medicine and Department of Epidemiology Public Health Informatics, Korea University School of Public Health
-
- Kim Min-Jeong
- Korea University School of Public Health
-
- Lee Sang-Min
- Department of Internal Medicine, Armed Forces Capital Hospital
-
- Kim Seung-Young
- Department of Internal Medicine, Korea University College of Medicine
-
- Jeon Han-Ho
- Department of Internal Medicine, Yonsei University College of Medicine
Search this article
Abstract
The first large-scale outbreaks of respiratory disease in the 21st century were caused by the influenza A (H1N1) virus in 2009, which affected mostly young adults. The M59 vaccine was developed to control pandemic influenza A (H1N1). However, the complications arising from the use of the non-adjuvanted and adjuvanted vaccines in young male Korean soldiers have not previously been evaluated and compared. We conducted a prospective multicenter study of 2,864 healthy male soldiers aged 19 to 25 years to evaluate the adverse events associated with both the MF59-adjuvanted and non-adjuvanted forms of the influenza A/California/2009 (H1N1) surface-antigen vaccine. In most cases, the adverse-event symptoms were mild, and the most frequent adverse events were swelling at the injection site and myalgia, which were noted in 4.8% and 10.7% of participants, respectively. Administration of the MF59-adjuvanted vaccine was associated with an increased incidence of local (crude odds ratio [cOR], 1.56; 95% confidence interval [CI], 1.11–2.29) and systemic adverse events (cOR, 1.64; 95% CI, 1.29–2.07) after vaccination. Atopic dermatitis (adjusted OR [aOR], 2.32; 95% CI, 0.99–5.46) might be the choice risk factor for local adverse events, and adjuvant use (aOR, 1.35; 95% CI, 1.03–1.78) was a significant predictor of systemic adverse events in healthy young male Korean soldiers.
Journal
-
- Japanese Journal of Infectious Diseases
-
Japanese Journal of Infectious Diseases 65 (3), 193-197, 2012
National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee
- Tweet
Details 詳細情報について
-
- CRID
- 1390001206240736256
-
- NII Article ID
- 130001931803
-
- NII Book ID
- AA1132885X
-
- ISSN
- 18842836
- 13446304
-
- NDL BIB ID
- 023661164
-
- PubMed
- 22627298
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- Abstract License Flag
- Disallowed